Vor Biopharma Incorporated develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients.VOR33 is in phase 1/2 trials to treat acute myeloid leukemia and other blood cancers. Vor Biopharma was incorporated in 2015 and is headquartered in Cambridge, MA.